Topic: --NEW-- New hope for patients progressing after 1st-line treatment for mUCa
Earn accreditation points
Finish 5 cases, answer 10 questions and Earn 1 credit.
This topic consists of 5 cases
Disease Area: Bladder cancer
Background: The treatment algorithm has changed the last years. As recent as 2017, 2nd-line therapy for mUCa was either: re-exposure to 1st-line platinum-based therapy, vinflunine, taxane, best supportive care or clinical study. Luckily, times are changing...
Educational Objective: Gain insight in new treatment options for a patient population with very few options in the past
Specialty: Medical oncology, urology, clinical oncology, (radiation oncology)
Target Audience: CME (intermediate-advanced) | Residents (senior)
Latest update: August 2019